FDA withdraws approval of 3 PARP inhibitors to treat ovarian cancer
ADC评论
September 24, 2022
According to the FDA’s official website, the indications of three PARP inhibitors for the last-line treatment of ovarian cancer have been withdrawn, namely AstraZeneca’s olaparib,
